Market Cap 13.39B
Revenue (ttm) 464.37M
Net Income (ttm) -139.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 490.73
Profit Margin -30.08%
Debt to Equity Ratio 0.00
Volume 6,016,600
Avg Vol 2,014,608
Day's Range N/A - N/A
Shares Out 106.02M
Stochastic %K 96%
Beta 0.70
Analysts Sell
Price Target $115.47

Latest News on ITCI

J&J to buy Intra-Cellular Therapies for $14.6 billion

Jan 13, 2025, 6:38 AM EST - 4 days ago

J&J to buy Intra-Cellular Therapies for $14.6 billion

JNJ


This Stock Is Soaring Amid J&J Takeover Report

Jan 13, 2025, 5:41 AM EST - 4 days ago

This Stock Is Soaring Amid J&J Takeover Report


Intra-Cellular Brightens MDD Outlook With Caplyta Success

Jun 19, 2024, 2:08 AM EDT - 7 months ago

Intra-Cellular Brightens MDD Outlook With Caplyta Success


Intra-Cellular Therapies Prices Public Offering of Common Stock

Apr 17, 2024, 8:46 PM EDT - 9 months ago

Intra-Cellular Therapies Prices Public Offering of Common Stock


Intra-Cellular Therapies Is On Fire

Mar 11, 2024, 7:11 PM EDT - 11 months ago

Intra-Cellular Therapies Is On Fire